Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ORELABRUTINIB for Diffuse large b-cell lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 66 adverse event reports in the FDA FAERS database where ORELABRUTINIB was used for Diffuse large b-cell lymphoma.

Most Reported Side Effects for ORELABRUTINIB

Side Effect Reports % Deaths Hosp.
Anaemia 54 41.2% 8 5
Hypokalaemia 40 30.5% 2 0
Pneumonia 35 26.7% 8 3
Neutropenia 30 22.9% 3 0
Thrombocytopenia 26 19.9% 5 0
Disease progression 14 10.7% 3 0
Covid-19 11 8.4% 8 0
Platelet count decreased 11 8.4% 4 7
Drug ineffective 10 7.6% 6 0
Myelosuppression 10 7.6% 1 3
Product use in unapproved indication 8 6.1% 1 0
White blood cell count decreased 8 6.1% 1 2
Atrial fibrillation 7 5.3% 1 0
Febrile neutropenia 7 5.3% 2 0
Neutrophil count decreased 7 5.3% 1 2

Other Indications for ORELABRUTINIB

Central nervous system lymphoma (31) B-cell lymphoma (9) Chronic lymphocytic leukaemia (7) Mantle cell lymphoma (7) Non-hodgkin's lymphoma (5)

Other Drugs Used for Diffuse large b-cell lymphoma

RITUXIMAB (22,275) CYCLOPHOSPHAMIDE (16,598) DOXORUBICIN (15,213) VINCRISTINE (14,922) PREDNISONE (11,266) LENALIDOMIDE (7,858) ETOPOSIDE (4,698) PREDNISOLONE (4,086) CYTARABINE (3,857) DEXAMETHASONE (3,696)

Related Pages

ORELABRUTINIB Full Profile All Diffuse large b-cell lymphoma Drugs ORELABRUTINIB Demographics ORELABRUTINIB Timeline